Breathe Well Live Well
|
Impact of a pharmacist-led asthma and COPD respiratory clinic in general practice
The Pharmaceutical Journal Asthma and chronic obstructive pulmonary disease (COPD) continue to account for a large burden of disease in the UK. Despite comprehensive guidelines, more than 1,000 people die from asthma each year and COPD accounts for a leading cause of … |
View full post on asthma – Google News
The Pharmaceutical Journal |
Pharmacy interventions improve asthma outcomes
The Pharmaceutical Journal They found that nine out of ten studies reporting current asthma control showed a positive impact from pharmacy interventions. Interventions were also associated with improvement of asthma severity in three studies and asthma symptoms in eight studies. |
View full post on asthma – Google News
The Pharmaceutical Journal |
Very poorly controlled asthma lasts more than a decade for half of patients
The Pharmaceutical Journal The researchers, who presented their results at the American Thoracic Society International Conference on 15–18 May 2016, say that alternative treatment strategies and helping patients to quit smoking could improve the asthma control of these patients. |
View full post on asthma – Google News
|
We need more investment in diagnostics for asthma
The Pharmaceutical Journal Recent headlines in national media have declared that asthma is 'overdiagnosed and trivialised'. But as I am sure your readers know, these news stories are masking a deeper issue: there is no simple diagnostic test for asthma. It is shocking that in … |
View full post on asthma – Google News
|
Teva's injectable asthma biologic approved by FDA
The Pharmaceutical Journal The biologic treatment, which is given as a four-weekly infusion alongside other drugs, is indicated to help those patients with severe asthma who still have serious asthma attacks despite being on regular medication. It is expected to be launched in … |
View full post on asthma – Google News
Lung Disease News |
FDA Approves Teva's Cinqair for the Treatment of Severe Asthma
Pharmaceutical Technology Magazine (press release) (blog) FDA approved Teva Pharmaceutical's Cinqair (reslizumab) on March 23, 2016 for use with other asthma medicines for the maintenance treatment of severe asthma in patients 18 years and older. Cinqair is approved for patients who have a history of severe … FDA Approves Teva's Asthma Drug Cinqair as Add-on Treatment Nucala and Cinqair for the Treatment of Severe Asthma |
View full post on asthma – Google News
|
A simple intervention to help manage asthma patients
The Pharmaceutical Journal In asthma, prevention is vital to successful management of the condition. Preventer inhalers should be the mainstay of treatment and relievers should only be used if the patient is suffering symptoms. To health professionals this simple point is the … |
View full post on asthma – Google News
Pharmaceutical Processing |
Diverse asthma treatment pipeline presents major investment opportunity
Pharmaceutical Processing The active and diverse treatment pipeline for asthma boasts a striking level of innovation, with many first-in-class products representing significant investment opportunities, says business intelligence provider GBI Research. The company's latest … |
View full post on asthma – Google News
Bidness ETC |
Teva Pharmaceutical Industries Ltd Gets FDA Green Signal For Its Acute Asthma …
Bidness ETC Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA), the world's largest seller of generic drugs based in Israel, has yet another victory to add to its success story. Its acute asthma inhaler has finally pocketed the approval from the US Food and … First Breath-Actuated, Dry-Powder Inhaler for Acute Asthma Approved FDA approves ProAir RespiClick for treatment of acute asthma symptoms FDA clears Teva asthma med (TEVA) |
View full post on asthma – Google News
|
Report: U.S. Market for Asthma Treatment to See Modest Growth
Pharmaceutical Processing A new report expects the U.S. market for treatment asthma to grow from $11.7 billion in 2013 to $14 billion by 2020. The analysis by New York-based GBI Research predicted the recent expiration of patents for several of the top current therapeutics … |
View full post on asthma – Google News